AnaptysBioANAB
About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Employees: 136
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 34
4.93% more ownership
Funds ownership: 111.47% [Q3] → 116.39% (+4.93%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
16% less funds holding
Funds holding: 160 [Q3] → 135 (-25) [Q4]
39% less call options, than puts
Call options by funds: $21M | Put options by funds: $34.3M
48% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 52
58% less capital invested
Capital invested by funds: $1.13B [Q3] → $469M (-$659M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
JP Morgan Anupam Rama 23% 1-year accuracy 14 / 61 met price target | 121%upside $42 | Overweight Maintained | 5 Mar 2025 |
HC Wainwright & Co. Emily Bodnar 18% 1-year accuracy 29 / 161 met price target | 16%upside $22 | Neutral Reiterated | 4 Mar 2025 |
Wells Fargo Derek Archila 39% 1-year accuracy 12 / 31 met price target | 169%upside $51 | Overweight Maintained | 13 Feb 2025 |
Wedbush David Nierengarten 33% 1-year accuracy 39 / 117 met price target | 111%upside $40 | Outperform Maintained | 7 Feb 2025 |
Financial journalist opinion









